Try Seraph 100

EU

Providers

Treating COVID-19 with Seraph 100

The Seraph 100 binds with SARS-CoV-2, the virus that causes COVID-19. Clinicians have reported a reduction in inflammatory markers such as IL-6, d-dimer, and ferritin. Other anecdotal observations include improved hemodynamic stabilization, reduction of vasopressors and fractionally inspired oxygen, and avoidance or reduced time of mechanical ventilation.

Try Seraph 100

The Seraph 100:

  • Is the first device with an indication to reduce pathogens in the bloodstream in adjunction to antibiotic therapy*
  • Reduces a broad spectrum of drug-susceptible and drug-resistant pathogens
  • Can be used as an early intervention prior to pathogen identification
  • Has a novel biomimetic binding surface that prevents bacteria from developing resistance from it

Timestamps
00:00: Introductions
00:50: Seraph 100 Overview to Treat COVID-19 by Dr. Mink Chawla
12:35: Clinical Practice & Use of the Seraph 100 by Dr. Sean Barnett 
35:50: Questions and Answers  

 

Clinical Practice and Hands-On Experience:
User Case Study Presentations

Seraph 100 User Group III –
September 28, 2020

Clinicians review latest cases from Eisenhower Medical Center

Timestamps
00:00: Case Discussion
02:43: Introduction
03:45: Product Overview
06:44: Case Study Presentation
25:40: Q&A

 

Seraph 100 User Group II – September 4, 2020

Clinicians review COVID-19 Cases from Forrest General

Timestamps
00:00: Introduction 01:45: Product Overview
16:38: Case Study Presentation
37:34: Q&A

 

Try Seraph 100

Seraph 100 in the Field

Seraph 100 Microbind Affinity Blood Filter Technology

Seraph 100 is being used in hospitals across the United States, including several military hospitals. Several hospitals have presented their findings:

Walter Reed Medical Center: Treatment for Severe Coronavirus Disease 2019 With the Seraph-100 Microbind Affinity Blood Filter

Brooke Army Medical Center: USU COVID – 19 Clinical Performance Improvement Conference #19 Severe ARDS secondary to COVID Pneumonia

Dwight D. Eisenhower Army Medical Center: USU COVID – 19 Clinical Performance Improvement Conference #19 Seraph 100 Case Reports

Providers Using Seraph 100
in the United States

Please read our information sheet to learn more about the device and how to order it.

For FDA guidance on the use of Seraph 100 on COVID-19 patients, please follow the links below:

 

June 9, 2021
Clinical Use and Lessons Learned with Seraph 100

MAY 17, 2021
COVID-19 Webinar: A Role for Seraph 100

NOVEMBER 11, 2020
More Than Pathogen Reduction – Seraph 100 in COVID-19

JUNE 24, 2020
COVID-19 Webinar: A Role for Seraph 100

ExThera Medical Corporation
757 Arnold Drive, Suite B
Martinez, California 94553
p: (925) 839-2060 | f: (925) 839-2075
e: info@extheramedical.com

Seraph 100 News
Providers Investors
Patients About
DISCLAIMERS
*The Seraph® 100 Microbind® Affinity Blood Filter (Seraph) is CE Marked and approved for commercial sale in EU member states.
**Emergency Use Authorization Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) is for use in the United States under FDA EUA200165:
Authorization for Emergency Use in patients with COVID-19 admitted to the ICU with confirmed or imminent respiratory failure.
The Seraph 100 device has neither been cleared or approved for the indication to treat patients with COVID-19 infection.
The Seraph 100 device has been authorized by FDA under an Emergency Use Authorization (EUA).
The Seraph 100 device is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the Seraph device 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.